Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Diagnostics company Akers Biosciences nets $6.4mm in FOPO

Executive Summary

Akers Biosciences Inc. (rapid in vitro point-of-care screening and testing products) netted $6.4mm through a follow-on public offering of 21.5mm Class A units, including the overallotment, at $0.15 per unit (each Class A unit consists of one share of common stock and one warrant to purchase an additional common share) and 3.675k Class B Units (each Class B unit consists of one share of Series B convertible preferred stock (convertible into 24.5k common shares) and one warrant comparable to the Class A units) at $1k per unit. The warrants are exercisable for a five-year period at a strike price of $0.1875 per share. The company will use the offering proceeds to fund product development and marketing; to expand internal sales; and to further develop sales channels.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register